255 related articles for article (PubMed ID: 33363383)
1. PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases.
Sun C; Zhou F; Li X; Zhao C; Li W; Li J; Xiong A; Yu J; Gao G; Wang Q; Wu F; Zhou C
Onco Targets Ther; 2020; 13():12777-12786. PubMed ID: 33363383
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
[TBL] [Abstract][Full Text] [Related]
3. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
Front Immunol; 2022; 13():875488. PubMed ID: 35693805
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of PD-1 Inhibitors Combined with Anti-Angiogenic Therapy in Driver Gene Mutation Negative Non-Small-Cell Lung Cancer with Brain Metastases.
Song JQ; Wang X; Zeng ZM; Liang PA; Zhong CY; Liu AW
Discov Med; 2023 Jun; 35(176):321-331. PubMed ID: 37272099
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis.
Chen M; Wei L; Wang Q; Xie J; Xu K; Lv T; Song Y; Zhan P
Transl Lung Cancer Res; 2023 Apr; 12(4):689-706. PubMed ID: 37197616
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.
Huang L; Chen S; Liu H; Meng L; Liu C; Wu X; Wang Y; Luo S; Tu H; Wang C; Zhang M; Gong X
Cancer Med; 2024 Apr; 13(7):e7125. PubMed ID: 38613182
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.
Shepard MJ; Xu Z; Donahue J; Eluvathingal Muttikkal TJ; Cordeiro D; Hansen L; Mohammed N; Gentzler RD; Larner J; Fadul CE; Sheehan JP
J Neurosurg; 2019 Jul; 133(3):685-692. PubMed ID: 31349225
[TBL] [Abstract][Full Text] [Related]
8. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
Zhang T; Yang X; Zhao J; Xia L; Wang Q; Jin R; Zhou L; Zhang B; Zhao J; Li H; Li W; Xia Y
Front Oncol; 2021; 11():690093. PubMed ID: 34150659
[TBL] [Abstract][Full Text] [Related]
9. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
Lau SCM; Poletes C; Le LW; Mackay KM; Fares AF; Bradbury PA; Shepherd FA; Tsao MS; Leighl NB; Liu G; Shultz D; Sacher AG
Lung Cancer; 2021 Jun; 156():76-81. PubMed ID: 33932863
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
Gao G; Jia K; Zhao S; Li X; Zhao C; Jiang T; Su C; Ren S; Zhou F; Zhou C
Transl Lung Cancer Res; 2019 Dec; 8(6):920-928. PubMed ID: 32010570
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
Xu M; Shao K; Wang Y; Hao Y; Song Z
Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
[TBL] [Abstract][Full Text] [Related]
14. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of apatinib combined with whole-brain radiation therapy with a simultaneous integrated boost for brain metastases from non-small cell lung cancer: a multicenter retrospective study.
Ma J; Bi J; Tuo X; Pi G; Li Y; Li Y; Zeng F; Gong H; Hu D; Han G
J Thorac Dis; 2022 Feb; 14(2):455-463. PubMed ID: 35280489
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis.
Li S; Zhang H; Liu T; Chen J; Dang J
Front Oncol; 2021; 11():702924. PubMed ID: 34249764
[TBL] [Abstract][Full Text] [Related]
18. Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.
Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Yanagitani N; Horai T; Seike M; Gemma A; Nishio M
Thorac Cancer; 2020 Sep; 11(9):2465-2472. PubMed ID: 32657011
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
Yang K; Li J; Bai C; Sun Z; Zhao L
Front Oncol; 2020; 10():1098. PubMed ID: 32733805
[No Abstract] [Full Text] [Related]
20. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
